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Abstract: Introduction: The prevalence of diabetes mellitus (DM) and its morbidity and mortality are prominent all over
the world. Observational data suggest that vitamin D deficiency is associated with insulin resistance. In this
study, we aimed to assess this association. Methods: This study was a clinical trial consisting of 42 patients
with type 2 DM who had vitamin D deficiency. The patients underwent vitamin D replacement with vitamin
D pearls (50,000 iu) weekly for 10 weeks. The level of low-density lipoprotein (LDL), high-density lipoprotein
(HDL), cholesterol (Chol), triglycerides (TG), hemoglobin A1c (HbA1C), 2 hour post prandial (2HPP), fasting
blood sugar (FBS), body mass index (BMI), blood pressure (BP), and 25oHVitD3 were measured before and after
the treatment in all patients. Data were analyzed with paired t test. Results: 100% of patients reached acceptable
vitamin D level (above 30 mg/dl). No toxicity was reported. Changes in FBS, 2Hpp, HbA1C, Chol, SBP were
significant and there was no significant change in LDL, HDL, and DBP. Conclusion: Screening for vitamin D
deficiency and its replacement may have a beneficial effect on type 2 DM management and its associated risk
factors. More studies with larger sample size and use of placebo are recommended.
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1. Introduction
According to the report of the International Diabetes Feder-
ation, in 2019, about 463 million people with diabetes melli-
tus (DM) lived in the world and it is estimated that this num-
ber will reach more than 700 million in 2045. Also “374 mil-
lion people are at increased risk of developing type 2 DM”
(1). Over the past two decades, the global prevalence of DM
has increased significantly (2). In the management of DM,
considering a good glycemic control is important to reduce
∗Corresponding Author: Seyed Alireza Ebadi; Address: Imam Hossein Hos-
pital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email:
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the risk of complications. The optimal level of HbA1c in the
management of patients with DM is <7% (3). Therefore, try-
ing to control this chronic metabolic disease and prevent its
widespread complications is one of the priorities of health
care systems. In addition to using lifestyle modification and
blood sugar control drugs, controlling risk factors associated
with this disease is of considerable importance.
Vitamin D deficiency is significantly more prevalent among
different age and sex groups in all communities, including
Iran (4-6). In addition to its crucial role in bone health, other
functions for vitamin D such as preventing cell prolifera-
tion in colorectal, prostate and breast malignancies as well
as its role in autoimmune diseases have been identified (7).
High levels of 25-hydroxyvitamin D (25[OH]2D) are associ-
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ated with a lower risk of developing DM (8, 9). Also, a signif-
icant association between 25(OH)2D and HbA1c level is de-
tected and after adjustment for DM duration, type of medica-
tion, and complications, in addition to hypertension and ed-
ucation level, vitamin D deficiency may be an independent
predictor for poor glycemic control (10). The effect of Vita-
min D on DM is not exactly understood but it may poten-
tially promote beta-cell survival by modulating immune re-
sponse and decreasing systemic inflammation, enhance in-
sulin sensitivity by inducing insulin receptor expression, and
affect beta-cell function by changing the calcium flux (11).
Based on recent in vitro and in vivo articles on vitamin D
and insulin sensitivity, it has been shown that vitamin D is
effective in the onset and progression of type 2 DM (12). De-
creased vitamin D leads to an increase in PTH, which in turn
increases intracellular Ca 2+ ions. Increased intracellular cal-
cium inhibits insulin receptors in target tissues and closes
the Glut4 channel. On the other hand, insulin secretion from
pancreatic beta cells depends on the concentration of intra-
cellular calcium (13). Studies in mice have shown that vi-
tamin D can directly stimulate insulin secretion (14). Some
other studies have also revealed the presence of specific re-
ceptors for vitamin D and the α1 hydroxylase enzyme, which
converts 25(OH)2D to 1,25(OH)2D3 in pancreatic beta cells
(15). These findings suggest a possible effect of vitamin D on
glucose homeostasis, pathophysiology, and the progression
of type 2 DM (16-18). One study showed that insulin resis-
tance (HOMAIR index) was higher in the group with type 2
DM and vitamin D deficiency than in individuals with type
2 DM without vitamin D deficiency (VitD>20ng/ml, P=0.037)
and Pearson correlation coefficient for 25oHVitD and insulin
in type 2 DM was negative (r=0.294). Moreover, vitamin D
was negatively correlated with HOMAIR in the whole sample.
Thus, due to the role of vitamin D in glucose metabolism, its
deficiency can lead to insulin resistance and DM (19). Par-
ildar and colleagues reviewed vitamin D therapy for glucose
metabolism and found that vitamin D therapy improves in-
sulin resistance in people with vitamin D deficiency and has
a positive effect on glycemic parameters. It was suggested
that vitamin D replacement be performed as an initial pre-
ventive intervention in insulin resistance syndrome (20).
A study on patients with type 2 DM and chronic kidney dis-
ease (CKD) showed that in patients with vitamin D defi-
ciency, median HbA1c levels were significantly higher com-
pared with those with normal vitamin D status and vitamin
D replacement was associated with a significantly low level of
HbA1c and may have potential benefits on glycemic control
in type 2 DM management (21). In contrast, in a review about
the association between micronutrients such as calcium and
vitamins D with glucose metabolism, Martini and colleagues
reported that there were no sufficient and strong evidence to
prescribe supplements to prevent or control DM. Therefore,
to prevent deficiencies and maintain health, people with DM
should receive the necessary micronutrients naturally and
from rich food sources. Also, more studies with higher statis-
tical samples and longer follow-up are needed to assess the
definite benefit of using supplements in people at higher risk
of DM and its complications (22).
Despite a report on significant improvement in HbA1c fol-
lowing vitamin D replacement therapy (23), a study on pa-
tients with insulin-naïve type 2 DM showed that vitamin D
supplementation in patients with vitamin D deficiency was
associated with a significant reduction in fasting blood sugar
(FBs), but reductions in HbA1c, fasting insulin and HOMA-IR
were not significant (24). A meta-analysis showed that ad-
ministration of oral vitamin D supplement reduces insulin
resistance but does not appear to affect FBS, HbA1c and fast-
ing insulin levels. But studies in which medication adjust-
ment during the intervention period was allowed and the
diversity of treatment used for the management of DM be-
tween studies may affect the results (25). However, the clin-
ical application and treatment effect of vitamin D deficiency
have received little attention, results have been limited, and
contradictory results have been obtained in studies. Also vi-
tamin D deficiency was not considered as the main inclusion
criteria, therefore the samples were mostly supplemented
without considering vitamin D deficiency.
On the other hand, DM is significantly associated with higher
risk of coronary artery disease and cardiovascular mortal-
ity (26). Studies show that low vitamin D level is an in-
dependent risk factor for coronary artery disease; more-
over, vitamin D deficiency and DM have synergistic effect
on pathogenic mechanisms of formation and progression of
coronary atheroma, such as endothelial dysfunction, vascu-
lar smooth muscle cell proliferation, increasing the produc-
tion of pro-inflammatory cytokines, and immune cell migra-
tion and infiltration (27). Bonakdaran and colleagues also
found that vitamin D replacement may have beneficial ef-
fects on reducing cardiovascular risk factors in patients with
DM (28).
Therefore, given the high prevalence of DM in the commu-
nity and the exorbitant costs imposed by its effects on the
health care system and on the other hand the simplicity of
screening and the possibility of treating vitamin D deficiency,
we decided to investigate the effect of vitamin D deficiency
treatment by assessing on controlling the course of type 2
DM and its associated risk factors (hypertension and hyper-
lipidemia) in order to better control DM, also taking steps to
prevent its complications.
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2. Materials and Methods
2.1. Study design
People with diagnosis of type 2 DM according to World
Health Organization referred to the endocrine and internal
medicine clinic of Imam Hossein Hospital were randomly
selected. Patients were invited to participate in the project
with sufficient explanations about the project and its results
and benefits, and their participation in the project was op-
tional. The study was approved by the Ethics Committee,
informed consent was taken and people were assured that
their data would remain confidential and that the results of
the project would be used without mentioning their names
and addresses.
Inclusion criteria were age under 85 years, BMI below
35, HbA1C level below 10%, and vitamin D deficiency
(25OHVitD3 level less than 20ng/ml), were considered to
match the statistical sample and prevent confounding fac-
tors. Exclusion criteria were kidney or liver disease, history
of kidney stones, hypercalcemia, pregnancy, use of drugs that
interfere with vitamin D and calcium metabolism, and severe
hypertension. The sample size of the study was calculated
based on the following formula: N = (Z1− α / 2 + Z1 − β)2(S12
+ S2
2)/d2 at 42 patients.
At the beginning of the study, the level of low-density
lipoprotein (LDL), high-density lipoprotein (HDL), choles-
terol (Chol), triglycerides (TG), hemoglobin A1c (HbA1C), 2
hour post prandial (2HPP), FBS, BMI, blood pressure (BP),
and 25oHVitD3 were measured in all patients. The serum
25(OH)2D, shows the sum of endogenous synthesis and di-
etary intake and is the most stable and reliable indicator of
vitamin D status.
All tests were performed in the same laboratory. HbA1C fac-
tor was measured by Direct Enzymatic HbA1C Assay method
and by DIAZYME kits and 25oHVitD3 by ELISA method us-
ing IMMUN DIOGNOSTIC kits. Also, BP of the patients
was measured in sitting position from the right arm, by per-
forming the standard protocol including after at least 5 min-
utes of rest. Then participants which all had vitamin D de-
ficiency, were treated with 50,000 units of vitamin D3 oral
pearls weekly for 10 weeks. During the follow-up period, the
patients’ daily activities and diet did not have any change
compared to before beginning of study and DM medications
were continued with the previous dose. Daily dairy con-
sumption was also recommended to provide the calcium re-
quirement. Participants were followed up by telephone at
specified intervals for the above. Cases that for any reason
had to change medications, diet or activity were excluded.
After three months, the above clinical and paraclinical data
were re-examined for each patient. Treatment of vitamin
D deficiency was monitored by measuring 25oHVitD3 level.
Calcium levels of blood and urine were also measured to de-
tect cases of toxicity.
2.2. Statistical analysis
Results were presented as mean, standard deviation (SD),
median, range, frequency and percentage. Paired t-test was
used to compare the results before and after vitamin D ad-
ministration and Pearson correlation to examine the rela-
tionship between BMI and Chol, TG, HbA1C, 2HPP, and FBS.
All analyzes were performed by SPSS 22.0 statistical software.
P values of 0.05 or less were considered statistically signifi-
cant.
3. Results
In this study, 30 (71.4%) women and 12 (28.6%) men partic-
ipated. Their age and BMI are mentioned in Table 1. The
mean BMI of the participants was 28.8 (min: 27.76, max: 35),
which did not change significantly at the end of the study.
The mean±SD level of 25oHVitD3 at the beginning of the
study was 15±4.1 ng/ml, and at the end of the study, vitamin
D deficiency of all participants was treated and 25oHVitD3
achieved the desired level of above 30ng/ml. The mean±SD
level of vitamin D at the end of the study was 45.3±14.6
ng/ml. During the study, no toxicity with vitamin D and Ca
was observed.
As shown in table 2, the level of FBS after taking vitamin D
in patients with DM decreased by 17.9 mg/dL (P=0.001) and
the levels of HbA1C and 2HPP decreased by 0.55% and 32.71
mg/dL respectively (P<0.001).
As shown in table 3, HDL levels decreased about 1 mg/dL af-
ter taking vitamin D, which was not statistically significant
(P=0.408). LDL levels decreased more than HDL after taking
vitamin D, although the amount of reduction was not sta-
tistically significant (P=0.065). While cholesterol levels de-
creased by about 21 mg/dL, and TG level decreased by about
14 mg/dL which are both statistically significant (P=0.003
and P=0.022, respectively).
Pearson correlation coefficient was used to examine the rela-
tionship between BMI and the other factors. There was a sig-
nificant positive correlation between BMI and TG (P=0.007).
There was also a positive correlation between BMI and 2Hpp,
FBS and cholesterol, while the correlation with HbA 1C was
negative, although none of these correlations were signifi-
cant (table 3).
Systolic blood pressure decreased significantly after taking
vitamin D (P<0.001), while diastolic blood pressure did not
decrease significantly (P=0.653, table 4). Of course, this re-
duction in systolic blood pressure was not clinically very sig-
nificant.
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4. Discussion
Due to the high prevalence of DM and its complications (1,
2) trying to control this chronic metabolic disease, consider-
ing a good glycemic control and prevent its widespread com-
plications is one of the priorities of health care systems. In
addition to using lifestyle modification and blood sugar con-
trol drugs, controlling risk factors associated with this disease
is of considerable importance. Many studies have reported
that vitamin D is associated with insulin secretion and type 2
DM (29, 30). Also, within its effect on parathyroid hormone,
calbindin and calcium concentration, as well as delta recep-
tor production activated by peroxisome proliferator, vitamin
D affects insulin sensitivity and also apoptosis induced by
β-cells inflammation (27, 31-33). In addition to the he high
prevalence of vitamin D deficiency in all communities (4, 5,
6), considering a place for screening vitamin D deficiency in
patients with type 2 DM and treating it if necessary, if it can
help control the course of DM, will certainly lead to reduced
mortality, morbidity, and the exorbitant costs of DM and its
complications, including hemodialysis, surgeries related to
diabetic foot and antibiotics needed to control the infection,
costs associated with the treatment of ocular and cardiac
complications. In recent years, several cross-sectional stud-
ies have been conducted on the relationship between these
two diseases, the results of which have not been conclusive.
Although studies showed that Vitamin D deficiency was asso-
ciated with higher risk of DM, higher HbA1c level and higher
mortality in patients with type 2 DM (34-39), the results of
prospective studies on vitamin D supplementation was con-
troversial. In this study, by examining the effect of vitamin D
deficiency treatment on the course of glycemic control, lipid
profile, and blood pressure in patients with type 2DM, the re-
sults showed that the treatment of vitamin D deficiency with
high dose of vitamin D3 (50,000 units weekly) for 10 doses,
has positive results at the level of 2Hpp, FBS, and HbA1C.
The results were consistent some of the studies and in con-
trast with some others. The discrepancy in the findings can
be related to several factors. In our study, the most important
inclusion criterion was vitamin D deficiency, but this has not
been the case in recent studies, and on the other hand, pos-
itive results are probably associated with high doses of vita-
min D.
Examination of blood pressure at the beginning and end of
the study confirmed that treatment with vitamin D may have
effect in reducing systolic blood pressure in patients with
DM. This result was consistent with some studies (28, 40) but
in contrast with others (41, 42). Considering the method of
administration and the dose used, it seems that similar re-
sults have been obtained in studies that have used high doses
of vitamin D.
Data analysis did not show the effect of vitamin D on HDL
and LDL levels, but a clear and significant effect of vitamin
D supplementation on Chol and TG levels which was con-
sistent with the results of study of Toxqui L et al (40). The
reasons for the discrepancy in the results may include dif-
ferences in race, differences in the form of supplementation
(oral or injectable), its dose, and duration of use. Consider-
ing the mechanism of vitamin D and its fatty soluble nature,
BMI may have an impact on the clinical effects of vitamin D
supplement (43). Therefore a study using placebo with larger
sample size and considering metabolic conditions of the pa-
tients is needed. Long-term follow-up should also be consid-
ered for patients treated with vitamin D.
5. Conclusion
According to the findings of this study, it can be stated that
screening for vitamin D deficiency and its treatment in the
management of patients with type 2DM can play a role in
better control of their disease. On the other hand, by con-
trolling other risk factors such as TG and blood pressure,
it is possible to help reduce the complications of the dis-
ease and metabolic syndrome. Considering the limitations
of this study, a randomized control trial study with the use of
placebo, larger sample size and considering metabolic condi-
tions of the patients is needed. Long-term follow-up should
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Table 1: Statistical population in terms of age and BMI.
Mean±SD Median(Range)
Age 58.67±8.32 60(30-72)
BMI before 28.8±3.4 27.76(22.34-35)
BMI after 28.6±3.5 27.76(22.34-35)
25(OH)vitD before 15±4.1
25(OH)vitD after 45.3±14.6
Table 2: Blood sugar factors in patients before and after administration of Vitamin D.
Mean±SD Median(range) T-value P-value
HbA1C before 7.65±1.04 % 7.5(6 to 9.8) %
HbA1C after 7.1±0.9 % 7(5.6 to 9) %
HbA1C difference 0.55±0.65 % 0.5(-0.9 to 2.6) % 5.53 <0.001
FBS before 153.1±30.41 mg/dL 149(91 to 210) mg/dL
FBS after 135.19±31.65 mg/dL 134.5(75 to 204) mg/dL
FBS difference 17.9±33.85 mg/dL 21.5(-63 to 106) mg/dL 3.43 0.001
2HPP before 213.14±48.27 mg/dL 211.5(131 to 339) mg/dl
2HPP after 180.43±35.55 mg/dL 174(116 to 247) mg/dL
2HPP difference 32.71±44.52 mg/dL 33(-75 to 188) mg/dL 4.76 <0.001
Table 3: Correlation between BMI and evaluated parameters after vitamin D administration.
Chol TG HbA1C 2HPP FBS
BMI Pearson Correlation 0.147 0.413 -0.124 0.261 0.175
P value 0.358 0.007 0.438 0.099 0.274
Table 4: Blood pressure of the patients before and after the vitamin D administration.
Mean±SD Median(Range) T-value P-value
SBP1 before 125.48±12.44 mmHg 125(110-170) mmHg
SBP after 120.83±8.83 mmHg 120(110-140) mmHg
SBP difference 4.64±7.84 mmHg 0(-5-30) mmHg 3.838 <0.001
DBP2 before 73.1±6.71 mm Hg 70(60-80) mmHg
DBP after 72.74±6.46 mmHg 70(60-80) mmHg
DBP difference 0.36±5.11 mmHg 0(-10-10) mmHg 0.453 0.653
1SBP: systolic blood pressure, 2DBP: diastolic blood pressure.
This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).
Downloaded from: www.jmp.iums.ac.ir
